The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Chronic heart failure and hypoalbuminaemia are linked to a poor antibody response at 3 months after the third dose of the ...

Arcturus has made progress in cost-cutting and focusing on CF and OTC deficiency. Click here to find out the factors that ...

The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still down about 32% for the year. Moderna has more on the science behind mRNA.

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

The inaccurate rumours refer to a study looking at excess deaths during the pandemic in the German city of Frankfurt am Main.

The world's first mRNA vaccine against Elephant Endotheliotropic Herpesvirus (EEHV) has reportedly shown promising results, ...

If we don’t invest in technologies like mRNA vaccines for pandemic influenza now, once a virus starts going human-to-human, ...

Discover how mRNA vaccines could revolutionize medicine by targeting 9 major diseases. Learn about breakthrough treatments ...